PortfoliosLab logo
IDXX vs. DXCM
Performance
Risk-Adjusted Performance
Dividends
Drawdowns
Volatility
Financials

Correlation

The correlation between IDXX and DXCM is 0.57, which is considered to be moderate. This suggests that the two assets have some degree of positive relationship in their price movements. Moderate correlation can be acceptable for portfolio diversification, offering a balance between risk and potential returns.


-0.50.00.51.0
Correlation: 0.6

Performance

IDXX vs. DXCM - Performance Comparison

The chart below illustrates the hypothetical performance of a $10,000 investment in IDEXX Laboratories, Inc. (IDXX) and DexCom, Inc. (DXCM). The values are adjusted to include any dividend payments, if applicable.

2,000.00%2,500.00%3,000.00%December2025FebruaryMarchAprilMay
3,386.54%
2,293.87%
IDXX
DXCM

Key characteristics

Sharpe Ratio

IDXX:

-0.20

DXCM:

-0.79

Sortino Ratio

IDXX:

-0.07

DXCM:

-0.80

Omega Ratio

IDXX:

0.99

DXCM:

0.85

Calmar Ratio

IDXX:

-0.14

DXCM:

-0.70

Martin Ratio

IDXX:

-0.38

DXCM:

-1.15

Ulcer Index

IDXX:

17.62%

DXCM:

38.51%

Daily Std Dev

IDXX:

32.93%

DXCM:

56.20%

Max Drawdown

IDXX:

-81.46%

DXCM:

-94.61%

Current Drawdown

IDXX:

-33.21%

DXCM:

-56.85%

Fundamentals

Market Cap

IDXX:

$35.06B

DXCM:

$27.99B

EPS

IDXX:

$10.66

DXCM:

$1.42

PE Ratio

IDXX:

40.59

DXCM:

50.27

PEG Ratio

IDXX:

3.71

DXCM:

1.10

PS Ratio

IDXX:

9.00

DXCM:

6.92

PB Ratio

IDXX:

22.20

DXCM:

13.36

Total Revenue (TTM)

IDXX:

$2.93B

DXCM:

$3.11B

Gross Profit (TTM)

IDXX:

$1.79B

DXCM:

$1.87B

EBITDA (TTM)

IDXX:

$940.32M

DXCM:

$724.50M

Returns By Period

In the year-to-date period, IDXX achieves a 14.01% return, which is significantly higher than DXCM's -9.66% return. Over the past 10 years, IDXX has outperformed DXCM with an annualized return of 21.92%, while DXCM has yielded a comparatively lower 15.25% annualized return.


IDXX

YTD

14.01%

1M

12.62%

6M

15.84%

1Y

0.71%

5Y*

11.77%

10Y*

21.92%

DXCM

YTD

-9.66%

1M

4.37%

6M

-0.31%

1Y

-44.18%

5Y*

-3.84%

10Y*

15.25%

*Annualized

Compare stocks, funds, or ETFs

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.


Risk-Adjusted Performance

IDXX vs. DXCM — Risk-Adjusted Performance Rank

Compare risk-adjusted metric ranks to identify better-performing investments over the past 12 months.

IDXX
The Risk-Adjusted Performance Rank of IDXX is 4040
Overall Rank
The Sharpe Ratio Rank of IDXX is 4141
Sharpe Ratio Rank
The Sortino Ratio Rank of IDXX is 3636
Sortino Ratio Rank
The Omega Ratio Rank of IDXX is 3535
Omega Ratio Rank
The Calmar Ratio Rank of IDXX is 4444
Calmar Ratio Rank
The Martin Ratio Rank of IDXX is 4444
Martin Ratio Rank

DXCM
The Risk-Adjusted Performance Rank of DXCM is 1414
Overall Rank
The Sharpe Ratio Rank of DXCM is 1111
Sharpe Ratio Rank
The Sortino Ratio Rank of DXCM is 1717
Sortino Ratio Rank
The Omega Ratio Rank of DXCM is 1111
Omega Ratio Rank
The Calmar Ratio Rank of DXCM is 99
Calmar Ratio Rank
The Martin Ratio Rank of DXCM is 2222
Martin Ratio Rank
The risk-adjusted ranks indicate the investment's position relative to the market. A rank closer to 100 signifies top-performing investments, while a rank closer to 0 might suggest underperformance, based on the selected ratio. The values are calculated based on the past 12 months of returns.

IDXX vs. DXCM - Risk-Adjusted Performance Comparison

This table presents a comparison of risk-adjusted performance metrics for IDEXX Laboratories, Inc. (IDXX) and DexCom, Inc. (DXCM). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.


The chart of Sharpe ratio for IDXX, currently valued at -0.20, compared to the broader market-2.00-1.000.001.002.003.00
IDXX: -0.20
DXCM: -0.79
The chart of Sortino ratio for IDXX, currently valued at -0.07, compared to the broader market-6.00-4.00-2.000.002.004.00
IDXX: -0.07
DXCM: -0.80
The chart of Omega ratio for IDXX, currently valued at 0.99, compared to the broader market0.501.001.502.00
IDXX: 0.99
DXCM: 0.85
The chart of Calmar ratio for IDXX, currently valued at -0.14, compared to the broader market0.001.002.003.004.005.00
IDXX: -0.14
DXCM: -0.70
The chart of Martin ratio for IDXX, currently valued at -0.38, compared to the broader market-10.000.0010.0020.00
IDXX: -0.38
DXCM: -1.15

The current IDXX Sharpe Ratio is -0.20, which is higher than the DXCM Sharpe Ratio of -0.79. The chart below compares the historical Sharpe Ratios of IDXX and DXCM, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.


Rolling 12-month Sharpe Ratio-1.00-0.80-0.60-0.40-0.200.000.20December2025FebruaryMarchAprilMay
-0.20
-0.79
IDXX
DXCM

Dividends

IDXX vs. DXCM - Dividend Comparison

Neither IDXX nor DXCM has paid dividends to shareholders.


Tickers have no history of dividend payments

Drawdowns

IDXX vs. DXCM - Drawdown Comparison

The maximum IDXX drawdown since its inception was -81.46%, smaller than the maximum DXCM drawdown of -94.61%. Use the drawdown chart below to compare losses from any high point for IDXX and DXCM. For additional features, visit the drawdowns tool.


-65.00%-60.00%-55.00%-50.00%-45.00%-40.00%-35.00%-30.00%December2025FebruaryMarchAprilMay
-33.21%
-56.85%
IDXX
DXCM

Volatility

IDXX vs. DXCM - Volatility Comparison

IDEXX Laboratories, Inc. (IDXX) and DexCom, Inc. (DXCM) have volatilities of 17.69% and 17.04%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.


6.00%8.00%10.00%12.00%14.00%16.00%18.00%December2025FebruaryMarchAprilMay
17.69%
17.04%
IDXX
DXCM

Financials

IDXX vs. DXCM - Financials Comparison

This section allows you to compare key financial metrics between IDEXX Laboratories, Inc. and DexCom, Inc.. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.


Quarterly
Annual

Total Revenue: Total amount of money received from sales and other business activities


400.00M600.00M800.00M1.00B1.20BAprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
954.29M
1.11B
(IDXX) Total Revenue
(DXCM) Total Revenue
Values in USD except per share items

IDXX vs. DXCM - Profitability Comparison

The chart below illustrates the profitability comparison between IDEXX Laboratories, Inc. and DexCom, Inc. over time, highlighting three key metrics: Gross Profit Margin, Operating Margin, and Net Profit Margin.

Gross Margin
Operating Margin
Net Margin
Quarterly
Annual

60.0%65.0%70.0%AprilJulyOctober2021AprilJulyOctober2022AprilJulyOctober2023AprilJulyOctober2024AprilJulyOctober
59.8%
58.7%
(IDXX) Gross Margin
(DXCM) Gross Margin
IDXX - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, IDEXX Laboratories, Inc. reported a gross profit of 570.66M and revenue of 954.29M. Therefore, the gross margin over that period was 59.8%.
DXCM - Gross Margin
Gross margin is calculated as gross profit divided by revenue. For the three months ending on May 2025, DexCom, Inc. reported a gross profit of 654.00M and revenue of 1.11B. Therefore, the gross margin over that period was 58.7%.
IDXX - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, IDEXX Laboratories, Inc. reported an operating income of 261.69M and revenue of 954.29M, resulting in an operating margin of 27.4%.
DXCM - Operating Margin
Operating margin is calculated as operating income divided by revenue. For the three months ending on May 2025, DexCom, Inc. reported an operating income of 188.90M and revenue of 1.11B, resulting in an operating margin of 17.0%.
IDXX - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, IDEXX Laboratories, Inc. reported a net income of 216.15M and revenue of 954.29M, resulting in a net margin of 22.7%.
DXCM - Net Margin
Net margin is calculated as net income divided by revenue. For the three months ending on May 2025, DexCom, Inc. reported a net income of 151.70M and revenue of 1.11B, resulting in a net margin of 13.6%.